This year a clinical trial will test a drug combination designed to bring lasting relief for people with panic disorder – a condition that can upend daily life and be notoriously difficult to treat.
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results